Search Results

With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy frexalimab, which is currently in Phase III trials for multiple sclerosis.

Arrowhead Pharmaceuticals, Inc. announced a $50 million milestone payment was received from Royalty Pharma plc.

Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.

Agios Pharmaceuticals, Inc., a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, announced that the company has agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier’s vorasidenib to Royalty Pharma.

Ascendis Pharma A/S and Royalty Pharma plc announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue.

PTC Therapeutics, Inc. announced an agreement with Royalty Pharma plc. to monetize up to $1.5 billion of the Evrysdi royalty stream.

Teva Pharmaceuticals International GmbH and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs.

Royalty Pharma plc and Ferring Pharmaceuticals announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment.

Ligand Pharmaceuticals Incorporated and Agenus Inc. announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program.

The deal with PTC Therapeutics increases Royalty Pharma’s stake to 13% of total royalties garnered by Evrysdi, the blockbuster drug for spinal muscular atrophy licensed and marketed by Roche.